• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/1/21 4:32:51 PM ET
    $SRNE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SRNE alert in real time by email
    SC 13G/A 1 tm214855d5_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    SORRENTO THERAPEUTICS, INC.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

     

    (Title of Class of Securities)

     

                 83587F202             

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    Page 2 of 6 Pages

      

    CUSIP No. 83587F202

     

    1

    Name of Reporting Person

     

    China In Shine Investment Limited

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    British Virgin Islands

     

     

     

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting person
    with

     

     

     

    5

     

    Sole Voting Power

     

    4,760,801(1)

     

    6

     

    Shared Voting Power

     

    0

     

    7

     

    Sole Dispositive Power

     

    4,760,801 (1)

     

    8

     

    Shared Dispositive Power

     

    0

     

    9

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,760,801 (1)

     

    10

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

     

    Percent of Class Represented by Amount in Row (9)

     

    1.8%(2)

     

    12

     

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    (1) Comprised of 4,210,801 shares of the Issuer’s common stock (“Common Stock”) held directly by China In Shine Investment Limited (the “Reporting Person”) and 550,000 shares of Issuer’s Common Stock issuable upon exercise of a warrant issued by the Issuer to the Reporting Person on June 13, 2018 (the “Warrant”).

    (2) Percentage based on: (a) 262,938,148 shares of Common Stock outstanding as of October 23, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020, plus (b) 550,000 shares of Common Stock issuable upon exercise of the Warrant.

     

     

     

     

    Page 3 of 6 Pages

     

    Item 1.

     

    (a)Name of Issuer

     

    Sorrento Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    4955 Directors Place

    San Diego, CA 92121

     

    Item 2.

     

    (a)Name of Person Filing

     

    China In Shine Investment Limited (the “Reporting Person”)

     

    (b)Address of Principal Business office or, if None, Residence

     

    Flat A, 35/F, Tower 5, The Legend, Jardine's Lookout, 

    No. 23 Tai Hang Drive, Hong Kong

     

    (c)Citizenship

     

    British Virgin Islands

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value (“Common Stock”)

     

    (e)CUSIP Number

     

    83587F202

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       
    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         
    (e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
       

     

     

     

     

    Page 4 of 6 Pages

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:
       
      4,760,801*
       

     

    (b)Percent of class:
       
      1.8%**

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    4,760,801*

     

    (ii)Shared power to vote or to direct the vote:

     

    0

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    4,760,801*

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    0

     

    *Comprised of 4,210,801 shares of Common Stock held directly by the Reporting Person and 550,000 shares of Common Stock issuable upon exercise of a warrant issued by the Issuer to the Reporting Person on June 13, 2018 (the “Warrant”)

     

    **Percentage based on: (a) 262,938,148 shares of Common Stock outstanding as of October 23, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020, plus (b) 550,000 shares of Common Stock issuable upon exercise of the Warrant.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

     

     

     

    Page 5 of 6 Pages

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    N/A

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 1, 2021

     

      China In Shine Investment Limited 
         
      By: /s/ Chit Fung
        Name: Chit Fung
        Title: Director

     

     

     

     

     

     

     

    Get the next $SRNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRNE

    DatePrice TargetRatingAnalyst
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings